Cullinan Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CGEM Nasdaq 2834 cullinantherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - May 8th, 2025 11:00 am
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States - Apr 29th, 2025 11:00 am
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - Apr 23rd, 2025 2:14 pm
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis - Apr 16th, 2025 11:00 am
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Feb 27th, 2025 12:00 pm
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Feb 24th, 2025 12:00 pm
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans - Jan 31st, 2025 2:46 pm
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - Jan 30th, 2025 12:00 pm
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy - Jan 29th, 2025 12:00 am
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - Nov 14th, 2024 3:01 pm
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Nov 7th, 2024 12:00 pm
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - Nov 5th, 2024 12:00 pm
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - Nov 4th, 2024 12:00 pm
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - Oct 16th, 2024 11:00 am
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus - Sep 17th, 2024 11:00 am
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus - Sep 16th, 2024 11:00 am
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 - Sep 14th, 2024 8:15 am
We Think Cullinan Therapeutics (NASDAQ:CGEM) Can Afford To Drive Business Growth - Aug 24th, 2024 1:28 pm
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - Aug 8th, 2024 11:00 am
Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$92m market cap decline as longer-term profits stay in the green - Jun 4th, 2024 12:52 pm